Skip to content
buyModerate

EcoR1 Capital, LLC bought $39M of ITOS

owner at iTeos Therapeutics, Inc.. 4,958,978 shares at an average of $7.80, traded May 14, 2025, filed May 16, 2025.

Conviction score
42
Value
$39M
4,958,978 shares
Holdings after
10,688,978
+87% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

Score components

  • Role
    10% owner
    +12
  • Trade size
    $38.7M at market
    +25
  • Relative to holdings
    Holdings up 87%
    +10
  • Price context
    No price history yet
    0
  • Cluster
    No other insider buying within 14 days
    0
  • Repeat buying
    First buy in 90 days
    0
  • Track record
    Too few past buys to judge (0 with prices)
    0
  • Outside holder
    A 10% owner who is not an officer or director
    -5

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Rows in this filing

Every transaction in Form 4 0000935836-25-000384, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
May 14, 2025POpen-market purchase
Common Stockindirect: See Note
+1,658,978$7.41$12M7,388,978May 16, 2025
May 15, 2025POpen-market purchase
Common Stockindirect: See Note
+3,300,000$8.00$26M10,688,978May 16, 2025

Related signals

Other insiders at iTeos Therapeutics, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
43Moderate
ITOSsell 210b5-1
iTeos Therapeutics, Inc.
Michel Detheux
Chief Executive Officer
$1.0M
104,565 shares
-72%
43Moderate
ITOSsell 210b5-1
iTeos Therapeutics, Inc.
Michel Detheux
Chief Executive Officer
$1.6M
156,847 shares
-109%
33Weak
ITOSsell 210b5-1
iTeos Therapeutics, Inc.
David Hallal
director
$1.2M
114,682 shares
-300%
53Moderate
ITOSsell 3
iTeos Therapeutics, Inc.
MPM BioVentures 2014, L.P.
other
$5.1M
630,191 shares
-23%
53Moderate
ITOSsell 3
iTeos Therapeutics, Inc.
Ansbert Gadicke
other
$8.3M
1,031,931 shares
-23%
53Moderate
ITOSsell 3
iTeos Therapeutics, Inc.
Mpm Bioventures 2018, L.p.
other
$5.1M
630,191 shares
-23%
31Weak
ITOSbuy
iTeos Therapeutics, Inc.
Matthew Gall
Chief Financial Officer
$39k
5,000 shares
+8%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

EcoR1 Capital, LLC bought $39M of ITOS | InsiderTell